"Any Little Opening": Whistleblowers Target New Kinds Of Pharma Conduct
Pharmaceutical companies have overhauled their marketing practices but continue to be hit with qui tam suits as whistleblowers come up with new kinds of claims against them.
You may also be interested in...
The Department of Justice is going after pharmaceutical companies for behavior that traditionally has been left to FDA for regulatory enforcement.
Making A Federal Case Of Marketing Abuses: FDA Trains OCI Staff On Developing Cases Worth Prosecuting
FDA is training investigators in its Office of Criminal Investigations on how to pursue cases against individuals for off-label drug promotion so that they are able to convince U.S. Attorneys' Offices to prosecute them.
Marc Hermelin pleads guilty to distributing oversized morphine sulfate tablets; he may be first pharma exec to be jailed for healthcare fraud.